Medtronic plc MDT NYSE

Medtronic plc (MDT) generated $2.74B in operating cash flow for quarter ending 2026-01-23. After capital expenditures of $444M, free cash flow was $2.3B.

Free cash flow margin was 25.5% of revenue. Cash conversion ratio was 2.4x, indicating earnings are backed by cash.

The company returned $911M in dividends and $105M in share buybacks to shareholders during the quarter.

Criteria supported by this page:

• HEALTH (83/100, Pass) — demonstrate the company can comfortably service its debt
• MOAT (86/100, Pass) — $2.3B (25.5% margin) supports a durable competitive advantage
• INCOME (55/100) — Cash conversion ratio was 2.4x confirms earnings are backed by real cash flow

Overall SharesGrow Score: 69/100 with 3/7 criteria passed.